Article
Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.
Proceedings of the National Academy of Sciences of the United States of America - 26 Sept 2000
Gnjatic S, Nagata Y, Jager E, Stockert E, Shankara S, Roberts B L, Mazzara G P, Lee S Y, Dunbar P R, Dupont B, Cerundolo V, Ritter G, Chen Y T, Knuth A, Old L J
Abstract excerpt
NY-ESO-1 elicits frequent antibody responses in cancer patients, accompanied by strong CD8(+) T cell responses against HLA-A2-restricted epitopes. To broaden the range of cancer patients who can be assessed for immunity to NY-ESO-1, a general method was devised to detect T cell reactivity independent of prior characterization of epitopes. A recombinant adenoviral vector encoding the full cDNA sequence of NY-ESO-1...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.